Trial Profile

Double Blind, Double Dummy, Randomised, Multicentre, Four Arm Parallel Group Study to Assess the Efficacy and Safety of FlutiForm pMDI 250/10microg (2 Puffs Bid) vs Fluticasone pMDI 250microg (2 Puffs Bid) Plus Formoterol pMDI 12microg (2 Puffs Bid) Administered Concurrently in Adult Subjects With Severe Persistent, Reversible Asthma.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Formoterol/fluticasone propionate (Primary) ; Fluticasone propionate; Formoterol
Indications Asthma
Focus Therapeutic Use

31 Dec 2010 Results published in Respiratory Medicine.
22 Sep 2010 Results presented at the 20th Annual Congress of the European Respiratory Society.
22 Sep 2010 Results for comparison between formoterol/fluticasone propionate and formoterol + fluticasone propionate were presented at the 20th Annual Congress of the European Respiratory Society.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com